FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.

ABSTRACT:

Background

Immunotherapies may prolong the survival of patients with small-cell lung cancer (SCLC) to some extent. The role of forkhead box protein P3 (FOXP3) in tumor microenvironment (TME) remains controversial. We aimed to examine FOXP3-related expression characteristics and prognostic values and to develop a clinically relevant predictive system for SCLC.

Methods

We enrolled 102 patients with histologically confirmed SCLC at stages I-III. Through immunohistochemistry, we determined the expression pattern of FOXP3 and its association with other immune biomarkers. By machine learning and statistical analysis, we constructed effective immune risk score models. Furthermore, we examined FOXP3-related enrichment pathways and TME traits in distinct cohorts.

Results

In SC

SUBMITTER: Jiang M 

PROVIDER: S-EPMC8137193 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature